Thoughts on health economics in rheumatoid arthritis
Author:
Open Access
- 1 November 2007
- journal article
- review article
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 66, iii35-iii39
Abstract
In this manuscript we discuss the reasons why and how health economics is important, the type of economic studies that are relevant in healthcare to different stakeholders in general, and what analyses can and have been performed in the field of rheumatoid arthritis (RA). We will thus specifically address costs and outcome measurements in RA, as well as the need for modelling in chronic progressive diseases.Keywords
This publication has 23 references indexed in Scilit:
- Modelling the cost effectiveness of TNF- antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics RegistryRheumatology, 2007
- Health economic issues in rheumatoid arthritisScandinavian Journal of Rheumatology, 2006
- Costs in rheumatology: results and lessons learned from the ‘Hannover Costing Study’Rheumatology International, 2005
- Analytic Choices in Economic Models of Treatments for Rheumatoid Arthritis: What Makes a Difference?Medical Decision Making, 2005
- TNF inhibitors in the treatment of rheumatoid arthritis in clinical practice: costs and outcomes in a follow up study of patients with RA treated with etanercept or infliximab in southern SwedenAnnals of the Rheumatic Diseases, 2004
- Modelling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UKRheumatology, 2003
- Economic evaluation of programs or interventions in the management of rheumatoid arthritis: defining a consensus-based reference case.2003
- The cost‐effectiveness of infliximab (Remicade®) in the treatment of rheumatoid arthritis in Sweden and the United Kingdom based on the ATTRACT studyRheumatology, 2003
- Estimating the cost-effectiveness of 54 weeks of infliximab for rheumatoid arthritisThe American Journal of Medicine, 2002
- Modeling the progression of rheumatoid arthritis: A two‐country model to estimate costs and consequences of rheumatoid arthritisArthritis & Rheumatism, 2002